You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Precision MRI with a Novel Protein Contrast Agent for Early Detection and Staging of Lung Fibrosis

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: NHLBI

    Summary Lung diseases, such as interstitial lung diseases including idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and acute viral infection are major leading causes of death worldwide. The recent increase due to air pollution, tobacco smoking is and use of E-cigarettes has grown rapidly in the US contributing to a sharp increase in chronic lung diseases. IPF is ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Ultra-low Fouling and Anti-infective and Anti-thrombotic Nitric Oxide Releasing Intravascular Catheters

    SBC: NYTRICX INC            Topic: NHLBI

    Abstract Nytricx is developing a new class of Nitric Oxide (NO)-releasing intravascular medical catheters to combat infection and thrombosis associated with indwelling vascular catheters. NO gas is a natural anti-infective and anti-thrombotic human product principally released from blood vessels and immune cells. Nytricx NO-releasing technology to the catheter surfaces via a polymer matrix, mimics ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Real-time Multimodal Diffuse Reflectance and Polarization Imaging Based Nerve Identification in Surgical Field of View

    SBC: YAYA SCIENTIFIC LLC            Topic: NIBIB

    PROJECT SUMMARY We propose to develop a novel non-contact, label-free multimodality imager that provides real-time intraoperative identification of nerves within the surgical field-of-view to facilitate the prevention of unintended nerve damage (termed iatrogenic nerve injury) during surgical procedures, as they are a major source of postsurgical complications, e.g., chronic pain. In the United St ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Optimizing Small Molecule Mechanomimetics to Treat Age-related Osteoporosis.

    SBC: OAK RIDGE THERAPEUTIC DISCOVERY LLC            Topic: NIA

    Abstract There is an unmet need to develop treatments for senile osteoporosis, a disorder characterized by an age-related reciprocal decrease in osteogenesis and increase in bone marrow fat. Senile osteoporosis resembles disuse osteopenia, suggesting its pathogenesis involves impaired bone mechanosensing. We discovered that the polycystin heterotrimeric complex (1PC1+3PC2) functions as a mechanose ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment

    SBC: SEAK Therapeutics, LLC            Topic: 106

    Project SummaryEpilepsy is one of the most common brain disorders. Current drugs have limited efficacy. Identifying new targeted drugs that can be used as safer, more effective therapies is in urgent unmet need. Selective inhibition of the transient receptor potential canonical 3 (TRPC3) emerges as a novel strategy to impede epilepsy. However, the currently best selective TRPC3 inhibitor, Pyr3, ha ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin) patch for the Treatment of Peanut Allergy

    SBC: MOONLIGHT THERAPEUTICS, INC.            Topic: NIAID

    The following contains proprietary/privileged information that Moonlight Therapeutics requests not be released to persons outside the government, except for purposes of review and evaluation Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within theSkin) patch for the Treatment of Peanut Allergy Food allergies affect 30 million people in the USA and 17 million in ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Non-Invasive Venous Waveform Analysis (NIVA) in patients with Heart Failure (HF)

    SBC: Volumetrix, LLC            Topic: NHLBI

    Project Summary Volume overload (congestion) occurs in patients with heart failure (HF) and is the leading cause of hospitalization in the elderly worldwide. Unfortunately, clinical signs and symptoms; laboratory values; and existing diagnostic tools are unreliable in providing accurate assessment of volume status. Using a unique physiologic signal, Non-Invasive Venous waveform Analysis (NIVA), Vo ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. A Low-Cost Wearable Connected Health Device for Monitoring Environmental Pollution Triggers of Asthma in Communities with Health Disparities

    SBC: WI-SENSE LLC            Topic: NHLBI

    Project Abstract Asthma affects 25 million Americans, and chronic obstructive pulmonary disease (COPD) affects 16 million,together costing 130 billion USD annually to the US healthcare system. Asthma is more prevalent in AfricanAmerican population (10.6%) than white population (7.7%). Poverty level has an impact as well, with twice asmuch asthma incidence in people below 100% of the poverty thresh ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Precision Guidance of Resuscitation and Deresuscitation in Sepsis

    SBC: DAXOR CORPORATION            Topic: 300

    ABSTRACT Sepsis impacts 1.7 million Americans annually, leading to 270,000 deaths and $62 billion in costs. Most of the sepsis treatment follows the Surviving Sepsis Campaign (SSC) guidelines, consisting of early antibiotics, liberal fluid resuscitation, and vasopressor use in persistent hypotension. However, the fundamental assumption that sepsis universally results in high capillary leak leading ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Enhanced renal dialysis membrane performance using lipocalin modified substrates

    SBC: HIBAR Microsciences, LLC            Topic: 400

    PROJECT SUMMARY: It is estimated that more than 30 million American adults have chronic kidney disease (CKD), with nearly 800,000 living with end-stage renal disease (ESRD). People with chronic diseases such as diabetes, high blood pressure, and heart disease are at a higher risk for CKD. Because their kidneys no longer function, individuals with ESRD often rely on hemodialysis to remove waste fro ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government